Test Waiver Justification Service
Endpoint-specific waiver support for ISO 10993 submissions using existing data, chemistry, toxicology, literature, and device context to produce reviewer-facing rationale that holds up better under scrutiny.
Endpoint-by-Endpoint Review
Waiver decisions made per endpoint, not through a blanket “not applicable” approach.
Existing Data Use
Literature, prior testing, equivalence, chemistry, and device history assessed for real waiver value.
Chemistry and TRA Integration
Chemistry and toxicology carried into the waiver logic where they are genuinely the strongest basis.
Reviewer-Facing Language
Rationale written so it can be reused directly in a BEP, BER, FDA summary, or response package.
Best for teams that want to avoid weak waiver statements and unnecessary testing
Good waiver strategy is not about removing evidence. It is about showing that the right evidence already exists. When the file explains that clearly, certain endpoints may not need new testing. When it explains it poorly, reviewer questions usually follow fast.
Existing Data Is Stronger Than the Current File Shows
You already have useful testing, chemistry, literature, or equivalence data, but the rationale is not being translated into a defensible waiver statement.
Chemistry May Support the Endpoint
Chemical characterization or TRA likely addresses part of the biological safety question, but the file does not connect it clearly.
Testing Decisions Need To Be Made Quickly
You want to decide whether a proposed test is truly needed before adding time, cost, and complexity to the project.
Reviewer Already Questioned a Waiver
FDA or a notified body asked for clarification because the current file uses weak, generic, or unsupported waiver language.
What strong waiver support actually needs to show
The file needs more than “not applicable.” It needs a clear scientific path showing how the biological risk is already addressed.
Endpoint-Specific Logic
Each endpoint is reviewed on its own merits, because the basis for waiving irritation is not necessarily the basis for waiving genotoxicity or implantation.
Existing Evidence Review
Prior testing, literature, device history, chemistry, and equivalence are examined for actual relevance to the finished device.
Chemistry and Toxicology Support
Where chemistry and TRA are central, they are carried into the rationale directly rather than referenced vaguely.
Gap Identification
Weak waiver areas are flagged honestly so the team knows where the science does not yet support the claim.
Reviewer-Facing Wording
The rationale is written in a way that answers the likely reviewer question instead of sounding generic or defensive.
Link Back to the Full File
The waiver logic is structured to fit the BEP, BER, and broader regulatory strategy rather than sit in isolation.
Situations where waiver quality usually changes the file materially
These are the projects where strong waiver support often saves time and prevents weak reviewer exchanges later.
Predicate or legacy evidence exists
Where earlier data may already address part of the endpoint strategy if it is framed correctly and matched to the finished device.
Chemistry is already strong
Where extractables, leachables, or TRA logic may support certain endpoint conclusions better than another generic test request.
Materials are well understood
Where long-used material systems or strong existing knowledge may justify more targeted evidence expectations.
Testing budget or timeline is tight
Where the goal is to determine quickly which endpoints truly need new work and which already have enough support.
Reviewer flagged a generic statement
Where a notified body or FDA has already made it clear that the current waiver language does not answer the scientific question.
Complex devices need a more selective strategy
Where a device with coatings, additives, or fluid pathways needs a more nuanced evidence plan than a checklist approach allows.
How waiver support is usually structured
The work starts with the endpoints in question, the evidence already available, and the exact reviewer or submission context.
Review Device and Endpoint Context
The contact profile, materials, pathway, and endpoints under discussion are reviewed first.
Assess the Existing Evidence
Testing, literature, chemistry, toxicology, and equivalence claims are checked for how directly they support the waiver.
Draft the Rationale
The waiver language is written to make the logic explicit, including what evidence supports it and what limitations remain.
Integrate It into the File
The final wording is shaped so it fits the BEP, BER, FDA section, or deficiency-response package cleanly.
Questions teams usually ask before starting waiver support
Can every endpoint be waived?
No. The point is not to waive everything. The point is to identify where the existing evidence genuinely supports a waiver and where it does not.
Does chemistry alone always justify a waiver?
No. Chemistry can be powerful, but it still has to fit the endpoint, the exposure scenario, and the device context appropriately.
Can this help after a reviewer comment?
Yes. That is one of the most practical use cases, especially when the original file relied on weak or generic waiver wording.
Is this separate from the BEP or BER?
It can be scoped separately, but in practice the rationale usually needs to feed directly back into the BEP, BER, or submission summary.
Need stronger waiver logic before the file goes out?
Send the device type, endpoints in question, current evidence package, and pathway. I will review the likely waiver scope and tell you the best next step.